Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy

•Patients with polycythemia vera (PV) often develop iron deficiency.•Treatment of PV with ruxolitinib is associated with normalization of iron indices.•Ruxolitinib was associated with improvements in patient-reported outcomes (PROs).•PRO improvements were more pronounced in patients with iron deficiency at baseline.